Harvard License Agreement Sample Clauses

Harvard License Agreement. XENO represents and warrants that the Harvard License Agreement has not at the date hereof expired, been terminated by either XENO or the President and Fellows of Harvard College and that XENO has not at the date hereof received nor given notice of termination for breach of the Harvard License Agreement. XENO represents and warrants to use all reasonable efforts to maintain the Harvard License Agreement, including, but not limited to complying with its obligations to pay the compensation due for the Harvard License Agreement.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
Harvard License Agreement. Harvard License Agreement shall mean the License Agreement effective as of July 5, 1994, by and between the President and Fellows of Harvard College and Millennium, as successor-in-interest to MyoGenics, Inc., as amended, and as may be amended from time to time in accordance with the provisions of Section 11.8.
Sample 1
Harvard License Agreement. Amounts payable under Section 3.2(a)(3) of the Harvard License Agreement with respect to distribution fees received by Millennium under Section 8.3 of this Agreement will be reimbursable under Section 8.6 of this Agreement.
Sample 1
Harvard License Agreement. XENO represents and warrants that the Harvard License Agreement has not, as of the Effective Date, been terminated by either XENO or the President and Fellows of Harvard College and that XENO has not, as of the Effective Date, received nor given notice of termination for breach of the Harvard License Agreement, and neither XENO nor Harvard is in default or breach of the Harvard License Agreement. XENO represents and warrants that it will use its best efforts to maintain the Harvard License Agreement and the exclusive licenses granted to XENO therein in full force and effect, which shall include, without limitation, (a) complying with its obligations to pay the royalties and other amounts owed Harvard pursuant to the Harvard License Agreement, and complying with all due diligence and commercialization obligations and milestones set forth in the Harvard License Agreement, (b) refraining from entering into any modification or amendment to the Harvard License Agreement that would in any way affect the rights under the XENO Patents granted to GENOMETRIX hereunder, and (c) taking no action or making no omission which will cause Harvard to have the right to terminate the Harvard License Agreement pursuant to its terms or rendering the exclusive licenses granted thereunder non-exclusive, and (d) taking any action to terminate the Harvard License Agreement. XENO agrees to notify GENOMETRIX of any written or oral notification by Harvard that XENO has breached the Harvard License Agreement or that Harvard wishes to terminate the Harvard License Agreement or render the exclusive licenses granted thereunder non-exclusive. XENO represents and warrants that it has the right under the Harvard License Agreement to grant to GENOMETRIX the rights and licenses granted herein. XENO represents and warrants that, should the Harvard License Agreement be terminated or rendered non-exclusive by Harvard, (i) the rights and licenses granted to GENOMETRIX under XENO's interest in the XENO Patents shall remain in full force and effect, and (ii) as set forth in EXHIBIT C hereof, GENOMETRIX shall continue to have a non-exclusive, worldwide, royalty bearing (as set forth in this Agreement) license under XENO's interest in the XENO Patents.
Sample 1
Harvard License Agreement. XENO hereby represents and warrants that (a) [***], the Harvard License Agreement has not at the date hereof expired or been terminated by either XENO or Harvard and that XENO has not at the date hereof received nor given notice of breach or termination for breach of the Harvard License Agreement [***] * Material has been omitted pursuant to a request for confidential treatment, and such material has been filed separately with the SEC. neither XENO nor Harvard is in default under the Harvard License Agreement. XENO covenants to use best efforts to maintain the Harvard License Agreement from the date of this Agreement through the term of the Harvard License Agreement, including, but not limited to (c) complying with its obligations to pay the compensation due for the Harvard License Agreement and (d) refraining from entering into any modification or termination of the Harvard License Agreement that would in anyway affect ROSETTA's rights to the Harvard Patents under this Agreement. In the event that the Harvard License Agreement is terminated, the sublicense granted to ROSETTA by XENO pursuant to Section 2.1.2 with respect to [***] will survive and any further sublicenses granted by ROSETTA to its sublicensee with respect to [***] shall survive.
Sample 1
Harvard License Agreement. The Company has provided to BVF a true and correct copy of the Company's agreement, as heretofore amended, with Harvard Medical School ("HMS") for an exclusive worldwide license for commercial applications for HMS's patented multiplex sequencing technology. Such agreement has not been terminated and the Company has received no notice or communication from HMS that the Company is in default thereunder.
Sample 1
Harvard License Agreement. The License Agreement (together with all Exhibits) entered into as of the 16th of May, 2016, by and between President and Fellows of Harvard College (“Harvard”) and ReWalk
Sample 1
AutoNDA by SimpleDocs

Related to Harvard License Agreement

  • License Agreement The Trust shall have the non-exclusive right to use the name "Invesco" to designate any current or future series of shares only so long as Invesco Advisers, Inc. serves as investment manager or adviser to the Trust with respect to such series of shares.

  • Sublicense Agreements Sublicenses shall be granted only pursuant to written agreements, which shall be subject and subordinate to the terms and conditions of this Agreement. Such Sublicense agreements shall contain, among other things, provisions to the following effect:

  • PATENT LICENSE AGREEMENT EXCLUSIVE PHS and Licensee agree as follows:

  • Software License Agreement McDATA agrees that all Licensed Software will be distributed to Customers subject to a Software License Agreement (including warranty statement), along with a McDATA Manual, in a manner which is (a) no less protective of BROCADE's Intellectual Property Rights in the Licensed Software than the form attached hereto as Exhibit D, and (b) legally enforceable in the jurisdictions in which the Licensed Software, as incorporated into the McDATA Products, is distributed.

  • License Agreements (a) Each Borrower and Guarantor shall (i) promptly and faithfully observe and perform all of the material terms, covenants, conditions and provisions of the material License Agreements to which it is a party to be observed and performed by it, at the times set forth therein, if any, (ii) not do, permit, suffer or refrain from doing anything that could reasonably be expected to result in a default under or breach of any of the terms of any material License Agreement, (iii) not cancel, surrender, modify, amend, waive or release any material License Agreement in any material respect or any term, provision or right of the licensee thereunder in any material respect, or consent to or permit to occur any of the foregoing; except, that, subject to Section 9.19(b) below, such Borrower or Guarantor may cancel, surrender or release any material License Agreement in the ordinary course of the business of such Borrower or Guarantor; provided, that, such Borrower or Guarantor (as the case may be) shall give Agent not less than thirty (30) days prior written notice of its intention to so cancel, surrender and release any such material License Agreement, (iv) give Agent prompt written notice of any material License Agreement entered into by such Borrower or Guarantor after the date hereof, together with a true, correct and complete copy thereof and such other information with respect thereto as Agent may request, (v) give Agent prompt written notice of any material breach of any obligation, or any default, by any party under any material License Agreement, and deliver to Agent (promptly upon the receipt thereof by such Borrower or Guarantor in the case of a notice to such Borrower or Guarantor and concurrently with the sending thereof in the case of a notice from such Borrower or Guarantor) a copy of each notice of default and every other notice and other communication received or delivered by such Borrower or Guarantor in connection with any material License Agreement which relates to the right of such Borrower or Guarantor to continue to use the property subject to such License Agreement, and (vi) furnish to Agent, promptly upon the request of Agent, such information and evidence as Agent may reasonably require from time to time concerning the observance, performance and compliance by such Borrower or Guarantor or the other party or parties thereto with the material terms, covenants or provisions of any material License Agreement.

  • Trademark License Agreement Buyer shall have executed and delivered to Sellers the Trademark License Agreement.

  • Third Party License Pursuant to 15 U.S.C. § 3710a(b)(1)(B), if PHS grants Collaborator an exclusive license to a CRADA Subject Invention made solely by an ICD employee or jointly with a Collaborator employee, the Government will retain the right to require Collaborator to grant to a responsible applicant a nonexclusive, partially exclusive, or exclusive sublicense to use the CRADA Subject Invention in Collaborator’s licensed field of use on terms that are reasonable under the circumstances; or, if Collaborator fails to grant a license, to grant a license itself. The exercise of these rights by the Government will only be in exceptional circumstances and only if the Government determines (i) the action is necessary to meet health or safety needs that are not reasonably satisfied by Collaborator, (ii) the action is necessary to meet requirements for public use specified by federal regulations, and such requirements are not reasonably satisfied by Collaborator; or (iii) Collaborator has failed to comply with an agreement containing provisions described in 15 U.S.C. § 3710a(c)(4)(B). The determination made by the Government under this Paragraph is subject to administrative appeal and judicial review under 35 U.S.C. § 203(2).

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Research License Following Selection of each CGI Antigen (or exercise of a Buy-In Right for each CGI Antigen) and subject to the terms and conditions of this Agreement, ABX agrees to grant, and hereby grants, to CGI a nonexclusive sublicense under the Licensed Technology to develop, make, have made, use, import or export or otherwise transfer physical possession of (but not to sell, lease, offer to sell or lease, or otherwise transfer title to) Covered Products related to such CGI Antigen and cells that express or secrete Antibodies to such CGI Antigen, in each case solely for purposes relating to or in connection with research or development (i) of Covered Products for use in the field of Gene Therapy or (ii) involving Genetic Material when used with viral or nonviral gene transfer systems. CGI shall have the right to sublicense the rights granted under this Section 2.5 upon the approval of ABX, which approval shall not be unreasonably withheld. In the event that ABX refuses to approve such a sublicense, ABX shall, to the extent that ABX has the right to do so, grant at CGI's request a nonexclusive sublicense of such rights directly to a non-Affiliate third party designated by CGI on terms and conditions substantially identical to the applicable terms and conditions of this Agreement. The sublicense granted by ABX under this Section 2.5 with respect to a CGI Antigen (and the further sublicenses, if any, granted by CGI under this Section 2.5 with respect to such CGI Antigen) shall terminate at such time as (A) CGI sends ABX an Abandonment Notice pursuant to Section 2.4.1 above regarding such CGI Antigen or (B) CGI enters into a CGI Product Sublicense related to such CGI Antigen; provided, however, that termination of a sublicense under this Section 2.5 with respect to a CGI Antigen pursuant to (B) above shall not affect the duration or survival of a grant of similar rights or sublicense under the CGI Product Sublicense with respect to such CGI Antigen, which rights or sublicense shall terminate or expire only in accordance with the terms of such CGI Product Sublicense. In the event that ABX enters into a Product Sublicense with respect to a CGI Antigen and CGI has not within six (6) months thereafter entered into a CGI Product Sublicense with respect to such CGI Antigen, the sublicense granted under this Section 2.5 with respect to such CGI Antigen shall terminate. It is understood and agreed that (x) as to ABX-Controlled Rights, the grant of rights under this Section 2.5 shall be subject to and limited in all respects by the terms of the applicable ABX In-License(s) pursuant to which such ABX-Controlled Rights were granted to ABX and (y) the rights and sublicenses granted to CGI under this Section 2.5 or any other provision of this Agreement shall be subject in all respects to the GenPharm Cross License.

  • Termination of License Agreement Without limiting the generality of the foregoing, in the event that the License Agreement is terminated in accordance with its terms, this Agreement, including without limitation any Purchase Order(s) or Project Work Orders then-in-effect, shall automatically terminate in its entirety as of the effective date of termination of the License Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.